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Carfilzomib (CFZ), an epoxyketone with 
specific chymotrypsin-like activity, is 
a second-generation proteasome inhi-
bitor with significant activity in pa-
tients with relapsed and refractory 
multiple myeloma. On July 20, 2012, 
the US Food and Drug Administration 
approved CFZ to treat patients with 
multiple myeloma who have received 
at least two prior therapies including 
bortezomib (BORT) and an immuno-
modulatory agent and have demon-
strated disease progression on or 
within 60 days of completion of the 
last therapy. Cytogenetic abnormal-
ities did not appear to have a sig-
nificant impact on the CFZ activity. 
Carfilzomib was well tolerated and de-
monstrated promising efficacy in pa-
tients with renal insufficiency. Poma-
lidomide (POM) (CC-4047) is a novel 
immunomodulatory derivative (IMID) 
with a stronger in vitro anti-myeloma 
effect compared with “older” IMIDs – 
thalidomide and lenalidomide (LEN). 
On February 8, 2013, the US Food and 
Drug Administration approved POM 
(Pomalyst, Celgene) for the treatment 
of MM patients who have received 
at least two prior therapies including 
LEN and BORT and have demonstrat-
ed progression on or within 60 days 
of completion of the last therapy. 
Pomalidomide is a novel IMID with 
significant anti-myeloma activity and 
manageable toxicity. This compound 
has shown high efficacy in MM pa-
tients who were resistant to prior use 
of LEN/BORT as well as in patients 
with a high-risk cytogenetic profile. 
Carfilzomib and POM have very high 
efficacy and will be used also in first 
line therapy in future.
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Carfilzomib (CFZ), an epoxyketone with specific chymotrypsin-like activ-
ity, is a second-generation proteasome inhibitor with significant activity in 
patients with relapsed and refractory multiple myeloma [1]. Carfilzomib se-
lectively inhibits activity of a chymotrypsin-like (β5) subunit of the 20S pro-
teasome and has minimal cross-reactivity with other protease classes. This 
inhibition is irreversible, as well as dose- and time-dependent in vitro and in 
vivo. As a result of proteasome inhibition we observe the accumulation of 
polyubiquitinated proteins and induction of apoptosis in many tumor cell 
lines including not only multiple myeloma but also Waldenström macroglob-
ulinemia, acute myeloid leukemia, B-cell malignancies (Burkitt’s and NHL), 
pancreatic cancer, and lung carcinoma [2, 3].
The efficacy of CFZ in heavily pretreated, relapsed and refractory multiple 
myeloma has been evaluated in a number of phase II trials. The pivotal PX-
171-003-A1 study of single-agent CFZ enrolled 266 patients [1]. The median 
age was 63 years and the patients had received a median of 5 prior ther-
apies including lenalidomide, bortezomib, thalidomide, alkylating agents, 
steroids, anthracyclines and transplants. Carfilzomib was administered in-
travenously (for 3 weeks in each 4-week cycle), twice weekly, at a daily dose 
of 20 mg/m2 in cycle 1 and then at a dose of 27 mg/m2 twice weekly for up 
to 12 cycles. The ORR was 23.7%, the clinical benefit response (CBR) was 
37%, the median PFS was 3.7 months and the median duration of response 
(DOR) was 7.8 months [CBR = ORR (sCR + CR + VGPR + PR) + MR (minimal 
response)]. The median OS in the group of patients refractory to both bor-
tezomib and lenalidomide was 11.9 months. Cytogenetic abnormalities did 
not appear to have a significant impact on CFZ activity. The ORR in patients 
with unfavorable cytogenetic or FISH findings was higher (29.6%) compared 
with patients with normal-favorable cytogenetics/FISH (22.8%), although 
the newest data revealed similar ORR in both groups but significantly higher 
OR in the standard risk group [4].
The study PX-171-004 with single-agent CFZ evaluated two groups of pa-
tients: the first bortezomib-naive and the second previously treated with 
bortezomib. In the bortezomib-naive cohort the ORR was 47.6% and CBR 
was 61.9% after six cycles of therapy [5]. In the bortezomib-treated co-
hort the ORR was 17.1% and CBR was 31.4%. The median DOR was > 10.6 
months, while the median time to progression (TTP) and median PFS were 
5.3 months [6]. 
Patients with renal insufficiency were evaluated in the PX-171-005 study. 
Carfilzomib was administered at a dose of 15 mg/m2 in cycle 1, then was 
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escalated to 20 mg/m2 in cycle 2 and to 27 mg/m2 from 
cycle 3 up to 12 cycles [7]. A similar assessment was sum-
marized in the study by Badros et al. [8]. The pharmacoki-
netics and safety of carfilzomib were not influenced by the 
degree of baseline renal impairment, including in patients 
on dialysis, and carfilzomib was well tolerated and demon-
strated promising efficacy [7, 8]. 
Carfilzomib has an acceptable tolerability profile. The 
incidence of grade 3 and 4 adverse events is low [9]. In the 
pivotal PX-171-003-A1 trial, grade 3 or 4 thrombocytopenia 
and anemia were observed in 29 and 24% of patients re-
spectively. They were not dose limiting and did not result 
in treatment discontinuation. In the PX-171-005 study the 
incidence of adverse events was independent of renal sta-
tus [7]. 
Recommended dosage of intravenous CFZ in relapsed, 
or relapsed and refractory, multiple myeloma is 20 mg/m2 
on days 1, 2, 8, 9, 15 and 16 of the 28-day treatment cycle. 
If the therapy is well tolerated in cycle 1, the dose should 
be increased to 27 mg/m2 in subsequent cycles. The maxi-
mum BSA to be used for dose calculation is 2.2 m2. Thera-
py with CFZ should be continued until disease progression 
or unacceptable toxicity occurs [10]. 
On July 20, 2012, the US Food and Drug Administration 
approved CFZ to treat patients with multiple myeloma 
who have received at least two prior therapies including 
bortezomib and an immunomodulatory agent and have 
demonstrated disease progression on or within 60 days of 
completion of the last therapy.
Several trials of CFZ were presented at the 2012 ASH 
meeting. There were the combination of CFZ with thalid-
omide and dexamethasone reported by Sonneveld et al. 
[11], and thalidomide, dexamethasone and cyclophospha-
mide reported by Mikhael et al. [12]. Palumbo et al. [13] 
presented the results of CCd (carfilzomib, cyclophospha-
mide and dexamethasone) in newly diagnosed, elderly 
MM patients. Korde et al. [14] presented a phase II clinical 
and correlative study of carfilzomib, lenalidomide, and 
dexamethasone (CRd) in newly diagnosed MM patients. 
Alsina et al. [15] presented a poster with updated results 
of a phase II study of cyclophosphamide, bortezomib, pe-
gylated doxorubicin, and dexamethasone (CVDD), in pa-
tients with newly diagnosed myeloma.
All these drug combinations have shown their effective-
ness in resistant, refractory MM patients. The results are 
encouraging, and need confirmation on larger cohorts of 
patients.
In conclusion, CFZ is a second-generation proteasome 
inhibitor with substantial activity in heavily pretreated 
multiple myeloma patients. Carfilzomib is well tolerated 
with a low number of patients discontinuing therapy due 
to adverse events. No peripheral neuropathy was connect-
ed with CFZ, even in patients with baseline symptoms. 
Carfilzomib was well tolerated and demonstrated promis-
ing efficacy in patient with renal insufficiency. 
We are also waiting for results of ongoing trials assess-
ing CFZ [ENDEAVOR Study: A Randomized, Open-Label, 
Phase 3 Study of Carfilzomib Plus Dexamethasone vs. 
Bortezomib Plus Dexamethasone in Patients with Re-
lapsed Multiple Myeloma. FOCUS Study: A randomised, 
Open-label, Phase 3 Study of Carfilzomib vs. Best Support-
ive Care in Subjects with Relapsed and Refractory Multi-
ple Myeloma. ASPIRE Study: A randomised, Multicenter, 
Phase 3 Study Comparing Carfilzomib, Lenalidomide, and 
dexamethasone (Crd) vs. Lenalidomide and Dexametha-
sone (Rd) in Subjects with Relapsed Multiple Myeloma], 
which may supply us with a fresh look at CFZ in multiple 
myeloma.
Another new drug in therapy of multiple myeloma is 
pomalidomide (CC-4047) – a novel immunomodulatory 
derivative (IMID) with a stronger in vitro anti-myeloma 
effect compared with “older” IMIDs – thalidomide and 
lenalidomide. IMIDs are found to be highly effective in 
myeloma patients and their anti-cancer activity includes 
several mechanisms. Namely, they may induce apoptosis 
via caspase-8, inhibit angiogenesis and cytokine secre-
tion, and impede the interactions between stroma and 
myeloma cells [16]. Finally, the protein cereblon (CRBN) 
has been recently identified as a target for IMIDs. Low 
CRBN expression was found to be associated with IMID 
resistance in myeloma cell lines. It was demonstrated 
that CRBN targets interferon regulatory factor 4, which 
plays a crucial role in myeloma cell survival. Moreover, it 
down-regulates tumor necrosis factor-α [17]. It has also 
been observed that decreased CRBN mRNA expression 
correlated with shorter progression-free survival and 
overall survival in patients with refractory and relapsed 
multiple myeloma (MM) [18]. 
The efficacy, safety and immunomodulatory effects 
of pomalidomide (POM) as a single agent in relapsed/re-
fractory MM have been explored in two phase I studies. 
A total of 24 MM patients were included in the study of 
Schey et al. [19]. The maximum tolerated dose was estab-
lished to be 2 mg daily. Nineteen out of the 24 patients 
continued the study beyond four weeks. It was demon-
strated that despite a median of three prior lines of ther-
apy including thalidomide and autologous hematopoietic 
stem cell transplantation (AHSCT), 67% of the patients 
achieved at least 25% reduction in monoclonal protein 
concentration, 54% experienced a greater than 50% de-
crease, and in 4 out of the 24 patients (17%) the criteria 
for complete response (CR) were met. Moreover, in vivo 
T-cell costimulation of this compound was also noted. 
Namely, it significantly increased serum interleukin (IL)-2 
receptor and IL-12 levels. It should be emphasized that 
POM was well tolerated and no serious non-hematologic 
adverse events were observed. However, regarding the 
safety concerns, there was a single report demonstrat-
ing a higher risk of deep vein thrombosis in MM patients 
on POM [20]. The same group reported on the results of 
a phase I study with alternate day POM. They included 
20 heavily pretreated patients and 50% of them achieved 
a greater than 50% decrease in paraprotein. 10% of in-
cluded patients met criteria for CR. The authors conclud-
ed that alternate day POM retained strong anti-myeloma 
activity whilst decreasing the incidence of thromboem-
bolism [21]. However, it should be noted that these stud-
ies were performed in a pre-bortezomib and pre-lena-
lidomide era. Recently, the results of a phase I study of 
POM in MM patients treated previously with bortezomib 
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(BORT) and lenalidomide (LEN) have been published. 
Oral POM was administered on days 1-21 of each 28-day 
cycle. Thirty-eight patients who had received a median 
of 6 prior therapies with BORT and LEN were included 
in this study. Dexamethasone (DEX) at 40 mg daily was 
allowed from the 4th cycle for those who progressed or 
had achieved less than a minimal response. The maxi-
mum tolerated dose of POM was established to be 4 mg 
for a 28-day cycle. Finally, DEX was added to POM in 22 pa-
tients. 21% of the patients achieved > 50% decrease of 
paraprotein and 3% fulfilled the CR criteria. The toxicity 
was manageable [22]. 
The first phase II study of POM in combination with 
low-dose DEX (POM/DEX) in relapsed MM enrolled 60 pa-
tients. Pomalidomide was administered orally at 2 mg 
daily on days 1-21 of a 28-day cycle, and DEX at 40 mg 
daily weekly. 63% of evaluated patients responded. 
Twenty patients (33%) achieved greater than very good 
partial response (VGPR), including 3 who met criteria for 
CR. The efficacy of this combination was also seen in 
patients previously refractory to thalidomide (37%), LEN 
(40%) and BORT (60%) treatment. Moreover, 74% of the 
patients with a high-risk cytogenetic profile responded 
to the therapy. Myelosuppression was the most com-
mon toxicity [23]. The Mayo Group reported the results of 
POM/DEX combination in MM patients refractory to LEN. 
Thirty-four patients were included in this study and the 
overall response rate (ORR) was 47% including 11 cases 
with at least a partial response (PR). The median overall 
survival (OS) was 13.9 months [24]. The same group com-
pared the efficacy of two different doses of POM (2 mg 
and 4 mg) in patients with dual refractoriness to LEN and 
BORT. DEX at 40 mg was administered weekly. A total of 
70 patients (35 in each cohort) were enrolled. No response 
to treatment in the 2-mg group was observed in 49% of 
patients whereas ORR was 43% for the 4-mg cohort. It 
should be emphasized that responses in both cohorts 
were rapid and durable, but the follow-up was too short 
to draw final conclusions. Overall survival at 6 months 
was estimated to be 78% and 67% for 2 mg and 4 mg 
groups respectively. Nevertheless, the results of this trial 
were highly encouraging if we consider the studied popu-
lation and that there was no dose-response effect. How-
ever, one should keep in mind the frequent occurrence 
of severe myelosuppression, especially neutropenia and 
thrombocytopenia, observed in this study. It may be par-
tially explained by refractoriness of the disease and prior 
treatment. The risk of thrombotic complications remained 
low while on low-dose DEX and adequate prophylaxis. 
11% of the patients had peripheral neuropathy of grade 
2 in both dose cohorts [25]. The follow-up results of the 
above-mentioned study based on 345 MM patients were 
presented during the ASH Meeting in 2012. At least PR 
was seen in 34% of the patients [26]. Recently, the results 
of two different dose regimens of POM/DEX in LEN and 
BORT refractory MM have been presented by the French 
Myeloma Group. Eighty-four patients with a median of 
5 prior lines of therapy were included in this randomized 
study. Pomalidomide at 4 mg daily was administered 
continuously for 28 days over a 28-day cycle or for 21 days 
of a 28-day cycle. ORR was similar between groups: 34% 
and 35% respectively. After the median follow-up of 23 
months, the median survival was 14.9 months with 44% 
of patients alive [27]. Finally, the largest multicenter ran-
domized phase III study to date comparing POM/DEX 
versus high-dose DEX alone was recently initiated. Four 
hundred and fifty-five patients with dual refractoriness 
(LEN and BORT or intolerant to BORT only) were enrolled 
in this study. Progression-free survival was significantly 
longer in the POM/DEX group compared with DEX alone 
(15.7 weeks vs. 8.0 weeks). A benefit regarding overall sur-
vival was also noted for this former subgroup (median not 
reached vs. 34 weeks) [28]. 
Combinations of POM with other agents were also test-
ed in patients with refractory and relapsed MM. Palumbo 
et al. presented the results of a phase I/II study of POM 
combined with cyclophosphamide and prednisone (PCP) 
in LEN refractory/relapsed patients. At least PR was doc-
umented in 73% of the patients resistant to LEN [29]. An 
overall response rate of 60% (including 27% meeting the 
criteria for very good partial response) in refractory MM 
patients was achieved with the combination of POM/DEX 
and clarithromycin [30]. 
The toxicity of POM/DEX combinations in heavily pre-
treated MM patients is acceptable. Neutropenia grade 
3/4 remained the major hematologic toxicity [26]. Among 
non-hematologic adverse events, fatigue was the most 
common complaint [25]. The frequency of thrombotic 
complications was low; they occurred in about 3% of pa-
tients [26]. A small proportion of patients may suffer from 
peripheral neuropathy [25] or noninfectious pulmonary 
injury [31].
On February 8, 2013, the US Food and Drug Adminis-
tration approved POM (Pomalyst, Celgene) for the treat-
ment of MM patients who have received at least two prior 
therapies including LEN and BORT and have demonstrat-
ed progression on or within 60 days of completion of the 
last therapy. This approval was based on the results of 
a phase II study with a total of 221 patients resistant to 
LEN/BORT. Patients were randomized to receive 4 mg dai-
ly POM alone for 21 days of a 28-day cycle vs. POM/DEX. 
At least PR was achieved in 15% and 34% of patients re-
spectively [32].
In conclusion, POM is a novel IMID with significant an-
ti-myeloma activity and manageable toxicity. This com-
pound has shown high efficacy in MM patients who were 
resistant to prior use of LEN/BORT as well as in patients 
with a high-risk cytogenetic profile.
Finally, although this article focuses primarily on these 
agents in the relapse setting, it should be noted that once 
evaluated in the relapse setting, these agents will ulti-
mately be evaluated in newly diagnosed patients. This is 
the case with an ongoing phase 3 clinical trial of elotu-
zumab plus lenalidomide and dexa metha sone, compared 
to lenalidomide and dexamethasone alone, in the front-
line treatment of myeloma. Also, once approved, many of 
these agents have increased efficacy when combined with 
different class drugs. For example, CRF, lenalidomide and 
dexamethasone is a very potent regimen for relapse and 
frontline therapy.
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In summary, the future pipeline for myeloma agents is 
very promising. Although myeloma represents only 1% of 
all cancers, six of the 21 agents approved over the past 12 
years to treat cancer have been for myeloma, and more 
myeloma agents appear on the horizon. Soon, we truly will 
be able to state with confidence that myeloma is a chronic 
disease with multiple treatment options that can control 
the disease for years.
Authors declare no conflict of interest.
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